# Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.

> **NCT01868048** · PHASE3 · WITHDRAWN · sponsor: **GW Research Ltd**

## Conditions studied

- Spasticity
- Multiple Sclerosis

## Interventions

- **DRUG:** Sativex
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01868048
- **Lead sponsor:** GW Research Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2017-06
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01868048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01868048, "Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01868048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*